Wave Life Sciences Ltd. (NASDAQ: WVE) released six‑month interim data from the Phase 1 portion of its first‑in‑human INLIGHT trial evaluating WVE‑007, an INHBE GalNAc‑siRNA therapy for obesity.
The data come from a 240 mg single‑dose cohort of 32 participants with an average BMI of 32 kg/m². Placebo‑adjusted reductions were 14.3 % in visceral fat, 5 % in total fat, a 2 % increase in lean mass, and a 3.3 % reduction in waist circumference. Serum Activin E remained suppressed for at least seven months, supporting the possibility of once‑ or twice‑yearly dosing.
These results demonstrate differentiated chemistry translating into clinically meaningful levels of fat loss, particularly harmful visceral fat, while preserving muscle. The durable suppression of Activin E suggests a convenient dosing schedule that could differentiate WVE‑007 from weekly injectable therapies.
Wave plans to begin the Phase 2a multidose portion of INLIGHT in the second quarter of 2026, targeting individuals with higher BMIs and comorbidities to evaluate greater weight‑loss efficacy. The company also continues development of other pipeline programs, including WVE‑006 for alpha‑1 antitrypsin deficiency and WVE‑008 for PNPLA3 I148M liver disease, and maintains a collaboration with GSK.
Investors reacted negatively to the announcement, citing mixed data interpretation—higher 400 mg dose results at three months were less impressive than the 240 mg dose at six months—alongside financial concerns. Wave’s Q4 2025 revenue declined and the company posted a net loss of $53.2 million, largely due to the termination of a collaboration with Takeda. Competitive pressures in the obesity market also weighed on sentiment.
Dr. Christopher Wright, Chief Medical Officer, said the results demonstrate differentiated chemistry translating into clinically meaningful levels of fat loss, particularly harmful visceral fat, while preserving muscle. President and CEO Paul Bolno added that WVE‑007 is already translating in the clinic with potent and durable Activin E reductions and it continues to be safe and well tolerated.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.